| 國立成功大學 |
2024-11-18 |
Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma
|
Tsai;Hui-Jen;Yeh;Kun-Huei;Lin;Chung-Wu;Wu;Ming-Shiang;Liou;Jyh-Ming;Hsu;Ping-Ning;Zeng;Yi-Shin;Wei;Ming-Feng;Shun;Chia-Tung;Wang;Hsiu-Po;Chen;Li-Tzong;Cheng;Ann-Lii;Kuo;Sung-Hsin |
| 國立成功大學 |
2024-11 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku;Narikazu;Omori;Takeshi;Shitara;Kohei;Sakuramoto;Shinichi;Yamaguchi;Kensei;Kato;Ken;Kadowaki;Shigenori;Tsuji;Kunihiro;Ryu;Min-Hee;Oh;Do-Youn;Oh;Cheul, Sang;Rha;Young, Sun;Lee;Keun-Wook;Chung;Ik-Joo;Sym;Jin, Sun;Chen;Li-Tzong;Chen;Jen-Shi;Bai;Li-Yuan;Nakada;Takashi;Hagihara;Shunsuke;Makino;Reina;Nishiyama;Eiji;Kang;Yoon-Koo |
| 國立成功大學 |
2024-08 |
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, pl
|
Kang;Yoon-Koo;Terashima;Masanori;Kim;Young-Woo;Boku;Narikazu;Chung;Cheol, Hyun;Chen;Jen-Shi;Ji;Jiafu;Yeh;Ta-Sen;Chen;Li-Tzong;Ryu;Min-Hee;Kim;Gwang, Jong;Omori;Takeshi;Rha;Young, Sun;Kim;Yong, Tae;Ryu;Won, Keun;Sakuramoto;Shinichi;Nishida;Yasunori;Fukushima;Norimasa;Yamada;Takanobu;Bai;Li-Yuan;Hirashima;Yoshinori;Hagihara;Shunsuke;Nakada;Takashi;Sasako;Mitsuru |
| 國立成功大學 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1) : updated overall survival from a randomised phase 3 study
|
Oh;Do-Youn;He;Ruth, Aiwu;Bouattour;Mohamed;Okusaka;Takuji;Qin;Shukui;Chen;Li-Tzong;Kitano;Masayuki;Lee;Choong-kun;Kim;Won, Jin;Chen;-Huang, Ming;Suksombooncharoen;Thatthan;Ikeda;Masafumi;Lee;Ah, Myung;Chen;Jen-Shi;Potemski;Piotr;Burris;Howard, A.;Ostwal;Vikas;Tanasanvimon;Suebpong;Morizane;Chigusa;Zaucha;Renata, E.;Mcnamara;Mairead, G.;Avallone;Antonio;Cundom;Juan, E.;Breder;Valeriy;Tan;Benjamin;Shimizu;Satoshi;Tougeron;David;Evesque;Ludovic;Petrova;Mila;Zhen;David, B.;Gillmore;Roopinder;Gupta;Govinda, Vineet;Dayyani;Farshid;Park;Oh, Joon;Jr, Buchschacher;Gary, L.;Rey;Felipe;Kim;Hyosung;Wang;Julie;Morgan;Claire;Rokutanda;Nana;Zotkiewicz;Magdalena;Vogel;Arndt;Valle;Juan, W. |
| 國立成功大學 |
2024-07-11 |
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study
|
Tsai;Hui-Jen;Shan;Yan-Shen;Yang;Ching-Yao;Hsiao;Chin-Fu;Tsai;Chung-Hsin;Wang;Chuan-Cheng;Lin;Ming-Tsan;Ting;Chun-Fu;Chan;De-Chuan;Chen;Te-Hung;Yen;Chueh-Chuan;Chen;Yen-Yang;Lin;Hsuan-Yu;Yeh;Ta-Sen;Ho;Ching-Liang;Shieh;Tze-Yu;Bai;Li-Yaun;Hsu;Jun-Te;Chen;I-Shu;Chen;Li-Tzong;Yeh;Chun-Nan;Liu;Tsang-Wu;Chuang;Chieh-Han;Wang;Tsang-En |
| 國立成功大學 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai;Hui-Jen;Yang;Shih-Hung;Hsiao;Chin-Fu;Kao;Hsiang-Fong;Su;Yung-Yeh;Shan;Yan-Shen;Yen;Chia-Jui;Du;Jeng-Shiun;Hsu;Chiun;Wu;I-Chen;Chen;Li-Tzong |
| 國立成功大學 |
2024-05 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang;Cheng-Yu;Yang;Shih-Hung;Li;Chung-Pin;Su;Yung-Yeh;Chiu;Sz-Chi;Bai;Li-Yuan;Shan;Yan-Shen;Chen;Li-Tzong;Chuang;Shih-Chang;Chan;De-Chuan;Yen;Chia-Jui;Peng;Cheng-Ming;Chiu;Tai-Jan;Chen;Yen-Yang;Chen;Jen-Shi;Chiang;Nai-Jung;Chou;Wen-Chi |
| 國立成功大學 |
2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan
|
Cheng;Muk, Siao;Su;Yung-Yeh;Chiang;Nai-Jung;Wang;Chih-Jung;Chao;Ying-Jui;Huang;Chien-Jui;Tsai;Hui-Jen;Chen;Shang-Hung;Chang;Chi-Yen;Tsai;Chia-Rung;Li;Yi-Jie;Yen;Chia-Jui;Chuang;Shih-Chang;Chang;Jeffrey, Shu-Ming;Shan;Yan-Shen;Hwang;Daw-Yang;Chen;Li-Tzong |
| 國立成功大學 |
2023-09-1 |
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized
|
Chiu;Yen-Feng;Liu;Tsang-Wu;Shan;Yan-Shen;Chen;Jen-Shi;Li;Chung-Pin;Ho;Ching-Liang;Hsieh;Ruey-Kuen;Hwang;Tsann-Long;Chen;Li-Tzong;Chang;Hui-Ju |
| 國立成功大學 |
2023-09 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
|
Su;Yung-Yeh;Chao;Ying-Jui;Wang;Chih-Jung;Liao;Ting-Kai;Su;Ping-Jui;Huang;Chien-Jui;Chiang;Nai-Jung;Yu;Yu-Ting;Tsai;Hong-Ming;Chen;Li-Tzong;Shan;Yan-Shen |
